BioVaxys partners with APVI to develop treatment for food allergies

VANCOUVER — BioVaxys Technology executes a binding Letter of Intent with Ontario’s AP Visionaries (APVI) to jointly develop a proprietary DPX formulation to treat or alleviate food allergies triggered by exposure to peanut/tree nuts or eggs.

BioVaxys and APVI are conducting the study in collaboration with The Schroeder Allergy and Immunology Research Institute (SAIRI) at McMaster University in Ontario.

The study will use animal models to assess the effectiveness of the DPX formulation in providing protection and altering the immunopathology of food allergies. BioVaxys will fund the study and retain all intellectual property rights. APVI will receive royalties from BioVaxys on any sales of the resulting product, along with a milestone payment upon regulatory approval.

Kenneth Kovan, president and COO of BioVaxys said, “Our ability to tackle this unmet medical need is directly attributable to the immune educating capability and highly flexible antigen loading capacity of our DPX platform. We see a staggering opportunity for continued expansion into other novel DPX-formulations with polynucleotides, peptides, proteins, virus-like articles, and small molecules.”

James Passin, CEO of BioVaxys, said, “Competing approved allergy desensitization treatments require weekly treatments, have the risk of anaphylaxis, and take years to complete – compliance with this therapy is very difficult for parents. Recently approved monoclonal antibody treatment carries a cost of US$ 2,900 and US$ 5,000 per month which could place treatment out of reach for some patients. We look forward to completing preclinical studies with our development partners, and anticipate an emerging profile for a single dose, long-duration, product consistent with other DPX formulations.”